Antimicrobial resistance (AMR) is a major global health security challenge. In 2019, 1.27 million people died worldwide as a direct result of drug-resistant bacterial infections, and a total of 5 million people lost their lives as a result of disease linked to AMR — not including drug-resistant tuberculosis, which is also a significant cause of death. In addition, a lack of available effective antibiotics threatens modern medicine as we know it today. Without these critical therapeutics, basic preventive and life-saving procedures that we take for granted become impossible, and hospital-acquired infections can run rampant.
For example, patients with cancer are particularly susceptible to infection, and AMR is the leading cause of non-cancer mortality in these individuals.
With so much at stake, there’s a lot of work to be done. However, developing new classes of antibiotics is highly challenging, both economically and scientifically. Scientifically, bacteria are a challenge to crack. “Bacteria are very complicated creatures, protected by outer membranes so they can live in hostile environments,” Michael explains. “It’s complicated to get through that outer membranes, and we don’t understand it well.” For decades, researchers have struggled to develop new chemical classes to circumvent resistance. And when they do develop a new approach, they often face another major challenge: the high doses of medicine needed to be effective may not be sufficiently safe in humans.
Overcoming these hurdles requires a sustained commitment to new and inventive approaches, regardless of potential setbacks. Roche is providing just such a dedicated commitment to not one, but two teams of scientists, one in in Pharma Research and Early Development (pRED) in Basel, Switzerland, and one in Genentech Research and Early Development (gRED) in South San Francisco, California, USA, who are both delivering exciting novel classes of antibiotics, which are currently in clinical development and research approaches to replenish the antibiotics pipeline.
Each research unit takes a slightly different approach to developing new antibiotic therapies. pRED collaborates with academic scientists to engage young scientists on this problem and “scour the earth, searching high and low” for new chemical scaffolds for these medicines, Michael says. These molecules are tested in both traditional and novel screens to find the most promising candidates, generating a wealth of information, and a team of experts across functions dedicated to developing antibiotics helps design the molecules for maximum efficacy and safety.
Meanwhile, gRED is integrating traditional laboratory approaches with a new strategy: using AI to find new molecules even expert chemists might not have thought of, or that don’t exist in nature. “By maintaining independent ways of approaching the problem, we don’t get into a herd mentality,”
However, he points out that the collaboration between pRED and gRED is also crucial: “We share expertise and reagents between pRED and gRED, and in this hub, we can further enrich the performance of each group. The screens that pRED is advancing generate high-quality data we can use in our AI model. The ‘we’ is what makes us special.”
Michael agrees. “We can leverage this synergy, and the
“This is a tough business, and innovation does not move fast,” Michael summarises. “But we have a young portfolio, and the foundation of Roche's commitment and support is a major driver behind our success.”
This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin.